The recently developed GPR133/ADGRD1 agonist AP50320 induces osteoblastogenesis in vitro and in vivo and significantly alleviates osteoporosis in vivo in an ovariectomy mouse model. This evidence concerns the gene ADGRD1 and osteoporosis.